Biologic Injections

Novel approaches to management of hives, eczema, asthma, nasal polyps and an ever-expanding array of other allergic conditions include therapies targeting key cells and mediators driving the inflammatory responses. These therapies, called biologics, are subcutaneous injections that are administered between every two and eight weeks in office or at home. 

Some examples include:

  • Xolair (omalizumab)
  • Fasenra (benralizumab)
  • Dupixent (dupilumab)
  • Nucala (mepolizumab)
  • Tezspire (tezepelumab-ekko)